Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.
As a privately-held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients.
Founded in 2008, Coriolis is the expert in the development of liquid and lyophilized formulations, process development for freeze-drying, as well as analytical services including GMP (Good Manufacturing Practice) and release analysis.
We have supported the successful development of many drug products and our scientists are eager to apply their experience on a large range of molecules (including proteins, peptides, monoclonal antibodies, nucleic acids, advanced therapy medicinal products (ATMPs), vaccines, viruses, virus-like particles and GMOs) to your project.
Webinars by Coriolis
Coriolis is the service partner with scientific excellence and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines. We believe that internal research projects are the scientific backbone of our high qualtiy services. That’s why we operate - since our foundation in 2008 - an academic research team within Coriolis and consult with a distinguished panel of experts on our scientific advisor board. This allows us to provide science-driven and tailor-made solutions to our clients.
Our webinar series is - besides peer-reviewed journal publications and podium presentations at conferences - a valuable way of sharing and discussing our scientific findings with the scientific community. Please note that some of our webinars are exclusive to our clients, partners and collaborators.
Nucleic acid-based medicinal products: Formulation considerations
Our scientific advisory board member Prof. Dr. Wim Jiskoot discusses how the stability of nucleic acid based medicinal products, including gene-therapy products and genetic vaccines, can be improved by means of formulation development.
Our motivation is to enable the development of innovative drugs by performing outstanding biopharmaceutical research to improve the quality of life for humankind.
We enable innovative therapies by revolutionizing formulation development.
We revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. We thereby enable future therapies to be made available to humankind efficiently and on time.
For us innovation is progress achieved by collaboration. We generate innovation by combining technologies, knowledge and experience.
Formulating for us means: to find the right solution.